Patents by Inventor Philip KLÖVEKORN

Philip KLÖVEKORN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20240116931
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 11, 2024
    Applicant: HEPAREGENIX GMBH
    Inventors: Brent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11858927
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 2, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Bent Praefke, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Stefan Laufer
  • PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20210078995
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: January 30, 2019
    Publication date: March 18, 2021
    Inventors: Bent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER